ARTICLE | Company News
Alkermes, Cephalon deal
June 27, 2005 7:00 AM UTC
ALKS partnered with CEPH to commercialize Vivitrex injectable extended-release naltrexone to treat alcohol dependence in the U.S. Vivitrex is under FDA review with a Sept. 30 PDUFA date. ALKS will re...